SRRK Scholar Rock
- 12.270
- -0.250-2.00%
Scholar Rock News
Express News | Scholar Rock Initiates Phase 2 EMBRAZE Trial Of Apitegromab In Obesity And Announces New Preclinical Data Showing SRK-439 Is 'More Potent Than an Anti-ActRII Antibody in Maintaining Lean Mass in Diet-induced Obesity (DIO) Mice'
Express News | Scholar Rock Holding Corp - Primary Data From Embraze Will Inform Scholar Rock's Development of Srk-439 Towards an Anticipated Ind Filing in 2025
Express News | Scholar Rock Holding Corp - Primary Data From Embraze Are Expected in Mid-2025
Express News | Scholar Rock Announces Initiation of Phase 2 Embraze Trial of Apitegromab in Obesity and New Preclinical Data Supporting Srk-439 in Obesity
Scholar Rock to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic dis
Does Scholar Rock Holding (NASDAQ:SRRK) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Scholar Rock Holding Price Target Maintained With a $30.00/Share by HC Wainwright & Co.
Scholar Rock Holding Price Target Maintained With a $30.00/Share by HC Wainwright & Co.
HC Wainwright & Co. Reiterates Buy on Scholar Rock Holding, Maintains $30 Price Target
HC Wainwright & Co. analyst Andres Maldonado reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Buy and maintains $30 price target.
Buy Rating Justified by Scholar Rock's Promising Pipeline and Strategic Clinical Advancements
Analysts Are Bullish on Top Healthcare Stocks: Scholar Rock Holding (SRRK), Zimmer Biomet Holdings (ZBH)
Scholar Rock Shares Fall on Wider-Than-Expected Q1 Loss
Scholar Rock (SRRK) shares were down 6.5% in recent Tuesday trading after the company's Q1 loss widened more than expected year-over-year. The company reported a Q1 net loss of $0.59 per diluted share
Scholar Rock | 10-Q: Quarterly report
Express News | Scholar Rock's Q1 Cash, Cash Equivalents And Marketable Securities Of $238M As Of March 31, Expected To Support Runway Into 2H 2025
Express News | Scholar Rock Holding Q1 2024 GAAP EPS $(0.59) Misses $(0.51) Estimate
Express News | Scholar Rock Holding Corp - Cash, Cash Equivalents Expected to Support Runway Into 2H 2025
Scholar Rock Holding Cash, Cash Equivalents and Marketable Securities of $238M as of March 31 Expected to Support Runway Into 2H 2025 >SRRK
Scholar Rock Holding Cash, Cash Equivalents and Marketable Securities of $238M as of March 31 Expected to Support Runway Into 2H 2025 >SRRK
Scholar Rock Holding 1Q Loss $56.9M >SRRK
Scholar Rock Holding 1Q Loss $56.9M >SRRK
Express News | Scholar Rock Reports First Quarter 2024 Financial Results and Highlights Business Progress
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Scholar Rock (NASDAQ:SRRK, the "Company")), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where
Scholar Rock Is A Potential M&A Target, Its Exploration of Obesity Market Garners Interest: Analyst
Raymond James has initiated coverage on Scholar Rock Holding (NASDAQ:SRRK), supported by the potential value with a couple of key programs utilizing selective myostatin inhibition to preserve muscle l
Analysis
Price Target
No Data
